Good morning :)
Place Order
Add to Watchlist

Glenmark Pharmaceuticals Ltd

GLENMARK

Glenmark Pharmaceuticals Ltd

GLENMARK
Health CarePharmaceuticals
MidcapWith a market cap of ₹43,531 cr, stock is ranked 210
Moderate RiskStock is 2.18x as volatile as Nifty
1,526.401.05% (-16.25)
1,526.401.05% (-16.25)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹43,531 cr, stock is ranked 210
Moderate RiskStock is 2.18x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹43,531 cr, stock is ranked 210
Moderate RiskStock is 2.18x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-49.745.550.16%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
58%
Analysts have suggested that investors can buy this stock

from 12 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

Investor Presentation

View older 

Nov 14, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 4.97%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 4.67% to 3.46%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue7,581.679,116.789,165.8210,240.7910,833.4511,038.6912,471.5712,339.1013,050.4213,280.26
Raw Materialssubtract2,442.743,073.932,904.863,421.013,570.563,809.434,396.424,498.194,608.9911,285.31
Power & Fuel Costsubtract120.47127.02137.48165.26173.69164.67200.64111.75124.00
Employee Costsubtract1,378.201,640.811,871.842,056.072,254.782,343.712,447.422,600.782,868.14
Selling & Administrative Expensessubtract1,395.791,589.861,523.271,750.211,667.021,453.551,543.271,752.301,708.60
Operating & Other expensessubtract787.32692.041,021.60887.121,276.841,088.191,657.761,751.062,208.99
Depreciation/Amortizationsubtract234.28264.37301.88325.91417.17443.55486.72569.17581.91536.49
Interest & Other Itemssubtract178.89237.32285.57334.59377.32353.11298.10349.04515.97370.96
Taxes & Other Itemssubtract300.94382.67315.46375.63320.11412.44499.54409.561,935.491,962.66
EPS26.8539.2928.4932.7827.5034.3833.3710.53-53.22-31.01
DPS2.002.002.002.002.502.502.502.502.502.50
Payout ratio0.070.050.070.060.090.070.070.24—-0.08

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2013

Annual Report Unavailable

Investor Presentation

Jan 9PDF
FY 2014

Annual Report Unavailable

FY 2015

Annual report

PDF

Investor Presentation

Jan 14PDF
FY 2016

Annual report

PDF

Investor Presentation

Jan 12PDF
FY 2017

Annual report

PDF

Investor Presentation

Jul 19PDF
FY 2023

Annual report

PDF

Investor Presentation

May 19PDF
Feb 10PDF
Nov 17PDF
FY 2024

Annual report

PDF

Investor Presentation

Sep 21PDF
Aug 11PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 14PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Glenmark Pharmaceuticals Ltd-28.995.550.16%
Sun Pharmaceutical Industries Ltd45.356.470.75%
Cipla Ltd28.514.380.89%
Torrent Pharmaceuticals Ltd68.4516.540.84%

Price Comparison

Compare GLENMARK with any stock or ETF
Compare GLENMARK with any stock or ETF
GLENMARK
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 2.07%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding46.65%11.41%1.80%23.05%17.09%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep25.52%24.80%23.71%21.38%20.98%23.05%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Glenmark Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan

Growth
2.7161%1.55%-0.22%21/78 (-2)
Mirae Asset Large & Midcap Fund - Growth - Direct Plan

Growth
1.1182%1.26%0.64%64/105 (+15)
Mirae Asset ELSS Tax Saver Fund - Growth - Direct Plan

Growth
0.8954%1.57%0.68%52/99 (+14)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

GLENMARK has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.16%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.62 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 13, 2024

Final
Final | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

Sep 13, 2024

Cash Dividend

Ex DateEx DateSep 18, 2023

Final
Final | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

Sep 18, 2023

Cash Dividend

Ex DateEx DateSep 12, 2022

Final
Final | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

Sep 12, 2022

Cash Dividend

Ex DateEx DateSep 8, 2021

Final
Final | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

Sep 8, 2021

Cash Dividend

Ex DateEx DateSep 17, 2020

Final
Final | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

Sep 17, 2020

News & Opinions
Spotlight
Glenmark Pharmaceuticals Ltd up for third straight session

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1566.05, up 1.2% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Glenmark Pharmaceuticals Ltd has slipped around 7.84% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has slipped around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 1.32 lakh shares today, compared to the daily average of 6.95 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 1569.85, up 0.78% on the day. Glenmark Pharmaceuticals Ltd is up 101.88% in last one year as compared to a 18.09% jump in NIFTY and a 38.64% jump in the Nifty Pharma index.The PE of the stock is 23.08 based on TTM earnings ending September 24.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Glenmark Pharma arm launches Travoprost Ophthalmic Solution in U.S market

Travoprost ophthalmic is used to treat glaucoma (a condition in which increased pressure in the eye can lead to gradual loss of vision) and ocular hypertension (a condition which causes increased pressure in the eye). Travoprost is in a class of medications called prostaglandin analogs. The newly launched drug is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Ophthalmic Solution USP of Sandoz, Inc. According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Ophthalmic Solution USP, market achieved annual sales of approximately $66.2 million. Jim Brown, senior vice president, sales & marketing said, 'We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers.' Glenmark currently has a portfolio of 200 products authorized for distribution in the U.S. marketplace and 51 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. The drug maker reported consolidated net profit from continuing operations of Rs 354.49 crore in Q2 FY25 as against net loss of Rs 180.3 crore in Q2 FY24. Revenue from operations increased 2.29% year on year (YoY) to Rs 3,133.79 crore in the quarter ended 30 September 2024. The scrip shed 0.14% to Rs 1,519.10 on the BSE. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Glenmark Pharma launches Travoprost Ophthalmic Solution USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z'2 Ophthalmic Solution USP, 0.004% of Sandoz, Inc. According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Z' Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Glenmark Pharmaceuticals Ltd eases for fifth straight session

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1526.05, down 0.5% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.34% on the day, quoting at 23452.35. The Sensex is at 77362.6, down 0.28%.Glenmark Pharmaceuticals Ltd has eased around 11.11% in last one month.Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has eased around 6.32% in last one month and is currently quoting at 21752, down 0.42% on the day. The volume in the stock stood at 9.98 lakh shares today, compared to the daily average of 6.27 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1533.95, down 0.46% on the day. Glenmark Pharmaceuticals Ltd jumped 94.35% in last one year as compared to a 19.08% rally in NIFTY and a 37.04% spurt in the Nifty Pharma index.The PE of the stock is 26.72 based on TTM earnings ending June 24.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Glenmark Pharma reports turnaround Q2 results

Revenue from operations increased 2.29% year on year (YoY) to Rs 3,133.79 crore in the quarter ended 30 September 2024. Profit before tax stood at Rs 472.57 crore in September 2024 quarter compared with pre-tax loss of Rs 124.35 crore posted in corresponding quarter previous year. EBITDA stood at Rs 601.9 crore in second quarter of FY25, registering a growth of 30.2% on YoY basis. During the quarter, EBITDA margin improved to 17.5% as against 14.4% in Q2 FY24. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. The counter closed 0.44% lower at Rs 1,531.70 on Thursday, 14 November 2024. The stock market is closed today on account of Guru Nanak Jayanti.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Glenmark Pharmaceuticals reports consolidated net profit of Rs 354.21 crore in the September 2024 quarter

Net profit of Glenmark Pharmaceuticals reported to Rs 354.21 crore in the quarter ended September 2024 as against net loss of Rs 81.95 crore during the previous quarter ended September 2023. Sales rose 7.59% to Rs 3400.50 crore in the quarter ended September 2024 as against Rs 3160.69 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3400.503160.69 8 OPM %17.7014.63 - PBDT592.85342.53 73 PBT472.57201.07 135 NP354.21-81.95 LP Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Glenmark Pharmaceuticals standalone net profit rises 96.81% in the September 2024 quarter

Net profit of Glenmark Pharmaceuticals rose 96.81% to Rs 595.06 crore in the quarter ended September 2024 as against Rs 302.35 crore during the previous quarter ended September 2023. Sales rose 19.56% to Rs 2594.89 crore in the quarter ended September 2024 as against Rs 2170.40 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2594.892170.40 20 OPM %30.0120.43 - PBDT849.91458.89 85 PBT795.06409.04 94 NP595.06302.35 97 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Glenmark Pharmaceuticals Ltd gains for third straight session

Glenmark Pharmaceuticals Ltd gained for a third straight session today. The stock is quoting at Rs 1757.95, up 1.9% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.85% on the day, quoting at 24419.55. The Sensex is at 80155.08, up 0.85%. Glenmark Pharmaceuticals Ltd has gained around 4.95% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 0.45% in last one month and is currently quoting at 22661.25, up 0.94% on the day. The volume in the stock stood at 3.12 lakh shares today, compared to the daily average of 6.36 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1758, up 1.44% on the day. Glenmark Pharmaceuticals Ltd is up 131.57% in last one year as compared to a 25.83% jump in NIFTY and a 49.79% jump in the Nifty Pharma index.The PE of the stock is 30.09 based on TTM earnings ending June 24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Glenmark Pharmaceuticals declare Quarterly Result

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Glenmark Pharmaceuticals Ltd spurts 2.21%

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1712.1, up 2.21% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.43% on the day, quoting at 24901.55. The Sensex is at 81363.7, up 0.39%. Glenmark Pharmaceuticals Ltd has risen around 0.46% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 0.73% in last one month and is currently quoting at 22977.8, up 0.86% on the day. The volume in the stock stood at 5.12 lakh shares today, compared to the daily average of 12.48 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1720.2, up 2.22% on the day. Glenmark Pharmaceuticals Ltd is up 118.27% in last one year as compared to a 27.62% spurt in NIFTY and a 53.45% spurt in the Nifty Pharma index.The PE of the stock is 29.21 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live